德曲妥珠单抗(T-DXd)治疗 HER-2 低表达乳腺癌的研究进展
摘要
关键词
全文:
PDF参考
Cortes J, Baselga J, Kellokumpu-Lehtinen P, et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2[J]. JCO. 2005,23(16):3068.
Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer[J]. New England Journal of Medicine, 2020,382(7):610-621.
André F, Park Y H, Kim S B, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2- positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet, 2023,401(10390):1773-1785.
Cortés J, Kim S B, Chung W P, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer[J]. New England Journal of Medicine, 2022,386(12):1143-1154.
Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer[J]. N Engl J Med, 2022,387(1):9-20.
Narayan P, Dilawari A, Osgood C, et al. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer[J]. JCO, 2023,41(11):2108-2116.
Tarantino P, Viale G, Press M F, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Annals of Oncology, 2023,34(8):645-659.
Bardia A, Harnden K, Mauro L, et al. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan[J]. Oncologist, 2022,27(8):637-645.
DOI: https://doi.org/10.12346/pmr.v5i3.8511
Refbacks
- 当前没有refback。